menu
    • menu
    [{"orgOrder":0,"company":"Aptinyx","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"NYX-2925","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ K2 HealthVentures","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ K2 HealthVentures"},{"orgOrder":0,"company":"Aptinyx","sponsor":"SVB Leerink","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"NYX-2925","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ SVB Leerink","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ SVB Leerink"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NYX-2925","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Syneos Health"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Rosalind Franklin University of Medicine and Science","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"NYX-2925","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Rosalind Franklin University of Medicine and Science","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Rosalind Franklin University of Medicine and Science"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NYX-2925","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Syneos Health"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NYX-2925","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Syneos Health"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NYX-2925","moa":"NMDA receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NYX-2925","moa":"NMDA receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Inapplicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NYX-2925","moa":"NMDA receptor","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aptinyx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for NYX-2925

    cayman pipeline prospector

    Virtual Booth

    Contact Supplier

    Check COS database
    Check USDMF database

    Contact Us
    PharmaScopic.com

    Click to view the API/FDF
    Pricing Demo Dashboard
    Menu

    NYX-2925

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aptinyx

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed

                            Aptinyx

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NYX-2925

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia

                            Details : NYX-2925 did not achieve statistically significant separation from placebo on the study’s primary endpoint, which assessed the change from baseline in average daily pain on the numeric rating scale (NRS) during week 12.

                            Product Name : NYX-2925

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 08, 2022

                            Lead Product(s) : NYX-2925

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aptinyx

                            U.S.A arrow
                            BPI Europe
                            Not Confirmed

                            Aptinyx

                            U.S.A arrow
                            BPI Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NYX-2925

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aptinyx Hosts Virtual Portfolio Review Event to Showcase NYX-2925 in Chronic Pain and Provide Update on Clinic...

                            Details : NYX-2925, NMDA receptor positive allosteric modulator currently under evaluation in Phase 2b study in patients with painful DPN and fibromyalgia has also exhibited favorable safety and tolerability profile across a wide dose range in clinical studies.

                            Product Name : NYX-2925

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 02, 2022

                            Lead Product(s) : NYX-2925

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aptinyx

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed

                            Aptinyx

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NYX-2925

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy

                            Details : NYX-2925, an oral NMDA receptor positive allosteric modulator did not achieve statistically significant separation from placebo on study’s primary endpoint, which assessed change from baseline in average daily pain on numeric rating scale (NRS) during ...

                            Product Name : NYX-2925

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 04, 2022

                            Lead Product(s) : NYX-2925

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aptinyx

                            U.S.A arrow
                            BPI Europe
                            Not Confirmed

                            Aptinyx

                            U.S.A arrow
                            BPI Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NYX-2925

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Fibromyalgia

                            Details : The Phase 2b study enrollment completed with 305 patients and, is evaluating the efficacy and safety of NYX-2925, a novel oral NMDA receptor positive allosteric modulator in patients with fibromyalgia.

                            Product Name : NYX-2925

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 28, 2022

                            Lead Product(s) : NYX-2925

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Aptinyx

                            U.S.A arrow
                            BPI Europe
                            Not Confirmed

                            Aptinyx

                            U.S.A arrow
                            BPI Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NYX-2925

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy

                            Details : In clinical studies, NYX-2925 has demonstrated activity that aects central pain processing, resulting in alleviation of pain and other symptoms associated with chronic pain conditions.

                            Product Name : NYX-2925

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 27, 2021

                            Lead Product(s) : NYX-2925

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Aptinyx

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed

                            Aptinyx

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NYX-2925

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Rosalind Franklin University of Medicine and Science

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Rosalind Franklin University Collaborates with Aptinyx to Research New Therapeutics for Brain Diseases

                            Details : Under the research agreement, investigators within the institute will partner with Aptinyx, which is developing novel therapies for neurologic disorders including NYX-2925, an oral small molecule NMDA receptor modulator in development for the treatment o...

                            Product Name : NYX-2925

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 22, 2021

                            Lead Product(s) : NYX-2925

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Rosalind Franklin University of Medicine and Science

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Aptinyx

                            U.S.A arrow
                            BPI Europe
                            Not Confirmed

                            Aptinyx

                            U.S.A arrow
                            BPI Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NYX-2925

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : K2 HealthVentures

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Aptinyx Secures $50 Million Growth Capital Credit Facility from K2 HealthVentures

                            Details : The funds will provide general growth as Aptinyx advances its late-stage clinical pipeline of novel NMDA modulators which includes NYX-2925, a novel, oral small molecule in development for the treatment of chronic pain.

                            Product Name : NYX-2925

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 16, 2021

                            Lead Product(s) : NYX-2925

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : K2 HealthVentures

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Aptinyx

                            U.S.A arrow
                            BPI Europe
                            Not Confirmed

                            Aptinyx

                            U.S.A arrow
                            BPI Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NYX-2925

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aptinyx Recommences Patient Recruitment in Phase 2 Study of NYX-2925 in Patients with Fibromyalgia

                            Details : Aptinyx has re-activated study sites and recommenced patient recruitment in a Phase 2 study of NYX-2925 in patients with fibromyalgia. Enrollment in the study had been suspended in March 2020 due to the escalation of the COVID-19 pandemic in the United S...

                            Product Name : NYX-2925

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 28, 2020

                            Lead Product(s) : NYX-2925

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Aptinyx

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed

                            Aptinyx

                            U.S.A arrow
                            PEGS Boston Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NYX-2925

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : SVB Leerink

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Aptinyx Announces Proposed Public Offering of Common Stock

                            Details : Aptinyx intends to use the net proceeds to advance the preclinical and clinical development of its novel NMDA receptor modulators, including NYX-2925, NYX-783, and NYX-458.

                            Product Name : NYX-2925

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 01, 2020

                            Lead Product(s) : NYX-2925

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : SVB Leerink

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth